77 related articles for article (PubMed ID: 20650313)
1. Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum-based chemotherapy.
Woolston CM; Deen S; Al-Attar A; Shehata M; Chan SY; Martin SG
Free Radic Biol Med; 2010 Nov; 49(8):1263-72. PubMed ID: 20650313
[TBL] [Abstract][Full Text] [Related]
2. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.
Su D; Smith SM; Preti M; Schwartz P; Rutherford TJ; Menato G; Danese S; Ma S; Yu H; Katsaros D
Cancer; 2009 Jun; 115(11):2453-63. PubMed ID: 19322891
[TBL] [Abstract][Full Text] [Related]
3. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
5. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
6. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.
Azuma K; Komohara Y; Sasada T; Terazaki Y; Ikeda J; Hoshino T; Itoh K; Yamada A; Aizawa H
Cancer Sci; 2007 Sep; 98(9):1336-43. PubMed ID: 17640298
[TBL] [Abstract][Full Text] [Related]
7. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
8. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma.
Kleinberg L; Flørenes VA; Silins I; Haug K; Trope CG; Nesland JM; Davidson B
Cancer; 2007 Jan; 109(2):228-38. PubMed ID: 17167759
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.
Harpole DH; Moore MB; Herndon JE; Aloia T; D'Amico TA; Sporn T; Parr A; Linoila I; Allegra C
Clin Cancer Res; 2001 Mar; 7(3):562-9. PubMed ID: 11297249
[TBL] [Abstract][Full Text] [Related]
10. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
11. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
[TBL] [Abstract][Full Text] [Related]
12. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
13. Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer.
Woolston CM; Storr SJ; Ellis IO; Morgan DA; Martin SG
Radiother Oncol; 2011 Aug; 100(2):308-13. PubMed ID: 21641069
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma.
Gadducci A; Viacava P; Cosio S; Fanelli G; Fanucchi A; Cecchetti D; Cristofani R; Genazzani AR
Anticancer Res; 2003; 23(1B):549-56. PubMed ID: 12680144
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.
Baekelandt MM; Holm R; Nesland JM; Tropé CG; Kristensen GB
Anticancer Res; 2000; 20(2B):1061-7. PubMed ID: 10810398
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer.
Huang J; Tan PH; Thiyagarajan J; Bay BH
Mod Pathol; 2003 Jun; 16(6):558-65. PubMed ID: 12808061
[TBL] [Abstract][Full Text] [Related]
17. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Vernaglia A; Sorio R; Tumolo S; Musso P; Magni G; Pisano C; Morabito A
Crit Rev Oncol Hematol; 2009 Sep; 71(3):233-41. PubMed ID: 19179095
[TBL] [Abstract][Full Text] [Related]
18. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
19. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
[TBL] [Abstract][Full Text] [Related]
20. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.
Bamias A; Psaltopoulou T; Sotiropoulou M; Haidopoulos D; Lianos E; Bournakis E; Papadimitriou C; Rodolakis A; Vlahos G; Dimopoulos MA
Cancer; 2010 Mar; 116(6):1462-8. PubMed ID: 20108307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
